EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Warfarin Pharmacogenomics: Designing Electrochemical DNA-Based Sensors to Detect CYP2C9*2 Gene Variation

Tiago Barbosa iD, Stephanie L Morais iD, Eduarda Pereira iD, Júlia M C S Magalhães, Valentina F Domingues iD, Hygor Ferreira-Fernandes, Giovanny Pinto iD, Marlene Santos iD, Maria Fátima Barroso

Genes · 2025

DOI: 10.3390/genes16040372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Tiago Barbosa und 8 weiteren Autor:innen. Beteiligte Einrichtung: REQUIMTE/LAQV, Escola Superior de Saúde, Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 400, 4200-072 Porto, Portugal. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C9, Warfarin, Polymorphism, Single Nucleotide, Electrochemical Techniques. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CYTED-rede Ibero-Americana project, FCT/MECI, Fundação para a Ciência e Tecnologia and Ministério da Educação, Ciência e Inovação.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The CYP2C9 enzyme is involved in the metabolism of warfarin. The CYP2C9 gene harbors several single-nucleotide polymorphisms (SNPs), including CYP2C9*2 (rs1799853), which is known to affect warfarin’s therapeutic response. So, it is important to develop analytical tools capable of genotyping these SNPs to adjust warfarin’s therapeutic outcomes. In this work, an electrochemical DNA-based sensor was constructed and optimized for the detection of the CYP2C9*2 polymorphism.

Methods

Using bioinformatic database platforms, two 71 base pair DNA target probes with the polymorphic variants A and G were chosen and designed. A DNA-based sensor was composed by mercaptohexanol and the CYP2C9*2 DNA capture probe in a self-assembled monolayer connected to screen-printed gold electrodes. Two independent hybridization events of the CYP2C9*2 allele were designed using complementary fluorescein-labeled DNA signaling to improve selectivity and avoid secondary structures. Three human samples with the homozygous variant (G/G) and non-variant (A/A) and heterozygous (G/A) genotypes were amplified by PCR and then applied to the developed genosensor.

Results

Chronoamperometry measurements were performed for both polymorphic probes. A calibration curve in the 0.25 to 2.50 nM (LOD of 13 pM) and another in the 0.15 to 5.00 nM range (LOD of 22.6 pM) were obtained for the homozygous non-variant and variant probes, respectively. This innovative tool was capable of identifying the hybridization reaction between two complementary strands of immobilized DNA, representing a genotyping alternative to the classical PCR methodology.

Conclusions

The developed electrochemical DNA-based sensor was able to discriminate two synthetic SNP target sequences (Target-A and Target-G) and detect, with specificity, the three patients’ genotypes (G/G, G/A, and A/A). This tool is therefore a promising, sensitive, and cost-effective analytical way to determine and discriminate an individual’s genotype and predict the appropriate warfarin dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C9WarfarinPolymorphism, Single NucleotideElectrochemical TechniquesBiosensing TechniquesPharmacogeneticsHumansDNAGenotypeAnticoagulants

Stichwörter der Autor:innen

CYP2C9*2cardiovascular diseaseselectrochemical DNA-based sensorpersonalized medicinepharmacogeneticssingle-nucleotide polymorphisms

Substanzen

Cytochrome P-450 CYP2C9WarfarinCYP2C9 protein, humanDNAAnticoagulants

Autor:innen und Institutionen

  • REQUIMTE/LAQV, Escola Superior de Saúde, Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 400, 4200-072 Porto, Portugal.
  • REQUIMTE/LAQV, Instituto Superior de Engenharia do Porto, Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 431, 4249-015 Porto, Portugal.
  • REQUIMTE/LAQV, Departamento de Engenharia Química, Faculdade de Engenharia, Universidade do Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.
  • Instituto de Educação, Ciência e Tecnologia Do Piauí (IFPI), Departamento de Informação, Ambiente, Saúde e Produção Alimentícia, 64019-368 Teresina, Brazil.
  • Grupo de Estudos Em Genética Humana e Médica (GEHMED), Laboratório de Genética e Biologia Molecular, Departamento de Biomedicina, Universidade do Delta do Parnaíba (UFDPar), 64202-020 Parnaíba, Brazil.
  • Grupo de Oncologia Molecular e Patologia Viral, Centro de Investigação, Instituto Português de Oncologia do Porto-Francisco Gentil, Rua Dr. António Bernardino de Almeida 865, 4200-072 Porto, Portugal.

ORCID-Profile: Tiago Barbosa, Stephanie L Morais, Eduarda Pereira, Valentina F Domingues, Giovanny Pinto, Marlene Santos

Förderung

  • CYTED-rede Ibero-Americana project
  • FCT/MECI, Fundação para a Ciência e Tecnologia and Ministério da Educação, Ciência e Inovação

Zitieren

APA

Barbosa, T., Morais, S. L., Pereira, E., Magalhães, J. M. C. S., Domingues, V. F., Ferreira-Fernandes, H., Pinto, G., Santos, M., & Barroso, M. F. (2025). Warfarin Pharmacogenomics: Designing Electrochemical DNA-Based Sensors to Detect CYP2C9*2 Gene Variation. Genes. https://doi.org/10.3390/genes16040372

Vancouver

Barbosa T, Morais SL, Pereira E, Magalhães JMCS, Domingues VF, Ferreira-Fernandes H, et al. Warfarin Pharmacogenomics: Designing Electrochemical DNA-Based Sensors to Detect CYP2C9*2 Gene Variation. Genes. 2025. doi:10.3390/genes16040372

BibTeX
@article{Barbosa2025,
  author = {Barbosa, Tiago and Morais, Stephanie L and Pereira, Eduarda and Magalhães, Júlia M C S and Domingues, Valentina F and Ferreira-Fernandes, Hygor and Pinto, Giovanny and Santos, Marlene and Barroso, Maria Fátima},
  title = {Warfarin Pharmacogenomics: Designing Electrochemical DNA-Based Sensors to Detect CYP2C9*2 Gene Variation},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16040372}
}
Kostenlos starten →